These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10616359)

  • 21. HIV-1 in semen: determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations.
    Ball JK; Curran R; Irving WL; Dearden AA
    J Med Virol; 1999 Nov; 59(3):356-63. PubMed ID: 10502269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.
    Solas C; Lafeuillade A; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    Antimicrob Agents Chemother; 2003 Jan; 47(1):238-43. PubMed ID: 12499197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments.
    Shepard RN; Schock J; Robertson K; Shugars DC; Dyer J; Vernazza P; Hall C; Cohen MS; Fiscus SA
    J Clin Microbiol; 2000 Apr; 38(4):1414-8. PubMed ID: 10747117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.
    Servais J; Peytavin G; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    AIDS; 2001 May; 15(7):941-3. PubMed ID: 11399971
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of antiretroviral therapy on HIV shedding in semen.
    Barroso PF; Schechter M; Gupta P; Melo MF; Vieira M; Murta FC; Souza Y; Harrison LH
    Ann Intern Med; 2000 Aug; 133(4):280-4. PubMed ID: 10929169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma.
    Böni J; Opravil M; Tomasik Z; Rothen M; Bisset L; Grob PJ; Lüthy R; Schüpbach J
    AIDS; 1997 May; 11(6):F47-52. PubMed ID: 9143600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.
    Pereira AS; Kashuba AD; Fiscus SA; Hall JE; Tidwell RR; Troiani L; Dunn JA; Eron JJ; Cohen MS
    J Infect Dis; 1999 Dec; 180(6):2039-43. PubMed ID: 10558966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
    Marcelin AG; Tubiana R; Lambert-Niclot S; Lefebvre G; Dominguez S; Bonmarchand M; Vauthier-Brouzes D; Marguet F; Mousset-Simeon N; Peytavin G; Poirot C
    AIDS; 2008 Aug; 22(13):1677-9. PubMed ID: 18670231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial.
    Grases F; García-González R; Redondo E; Costa-Bauzá A; Simonet BM; Sartini RP; Bassa A; Gallegos C; Payeras A; Saro D; Martinez AI; Cifuentes C; Homar F; Murillo JA; Fernández C; Riera M; Conte A
    Clin Ther; 2004 Dec; 26(12):2045-55. PubMed ID: 15823768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
    Celum CL; Buchbinder SP; Donnell D; Douglas JM; Mayer K; Koblin B; Marmor M; Bozeman S; Grant RM; Flores J; Sheppard HW
    J Infect Dis; 2001 Jan; 183(1):23-35. PubMed ID: 11106536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma.
    Winter AJ; Taylor S; Workman J; White D; Ross JD; Swan AV; Pillay D
    Sex Transm Infect; 1999 Aug; 75(4):261-3. PubMed ID: 10615314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
    Eron JJ; Smeaton LM; Fiscus SA; Gulick RM; Currier JS; Lennox JL; D'Aquila RT; Rogers MD; Tung R; Murphy RL
    J Infect Dis; 2000 May; 181(5):1622-8. PubMed ID: 10783117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
    AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission.
    Tachet A; Dulioust E; Salmon D; De Almeida M; Rivalland S; Finkielsztejn L; Heard I; Jouannet P; Sicard D; Rouzioux C
    AIDS; 1999 May; 13(7):823-31. PubMed ID: 10357382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.